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Abstract: 
The regioselective synthesis of estrogens and their derivatives continues to be of 
interest. Most reported syntheses require multistep protocols associated with 
poor overall yield and lack of regioselectivity. New preparative protocols are still 
desired. Herein, 11 2-alkylated 17β-estradiol analogs were synthesized in a highly 
regioselective manner. The products were obtained using a convenient, one pot and 
high-yielding protocol. The anti-proliferative activity of the compounds was tested in 
human T-cell leukemia (CEM), human cervix carcinoma (HeLa) and human dermal 
microvascular endothelial (HMEC-1) cells.  
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1. Introduction 
The estrogen 2-methoxyestradiol (2-ME, 1) was long believed to be an inactive 
endogenous metabolite of 17β-estradiol (2). However, in 1994, D´Amato, Folkman 
and co-workers showed that 2-ME (1) inhibits tubulin polymerization by interfering 
with the colchicine binding-site [1, 2]. Later studies revealed that the steroid 1 also 
blocks endothelial cell migration and proliferation in vitro [3]. Moreover, when 
administered to tumor-bearing mice, 2-ME (1) inhibited the vascularization and 
growth of solid tumors [2, 4].  In addition, it was reported that 2-ME (1) 
downregulates hypoxia-inducible factor-1α (HIF-1α) resulting in potent cytotoxic 
effects in prostate and breast cancer cells [5]. These observations were confirmed by 
in vivo studies that also showed that intrinsic and extrinsic apoptotic pathways were 
mediated by 2-ME (1) and its metabolites [6, 7]. 2-Methoxyestradiol (1) has entered 
several clinical trials that revealed no severe toxic effects, even when doses as high as 
3 grams per day were administrated [8-11].  
The aforementioned pharmacological activities have inspired several studies where 2-
ME (1) has been used as a lead compound for the development of new anti-cancer 
agents [12]. Some examples of such analogs are depicted in Figure 1.  
 
 
Fig. 1. Analogs of 2-ME (1) with anti-cancer  activities.  
 
We have previously used the steroid 1 as a lead compound for the synthesis of 
potential new anti-cancer agents [13-15]. The alkyl-substituent at C-2 seems 
interesting to alter in further efforts. The classic Friedel-Crafts reaction is the method 
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of choice for the introduction of secondary or tertiary alkyl groups in aromatic 
compounds, including phenols, such as 17β-estradiol [16, 17]. Although this method 
has been improved over the years the alkylation of primary alkyl groups is still a huge 
challenge  [17]. Most often this approach yields a mixture of rearrangement and 
polyalkylation products. Moreover, often harsh acidic or basic reaction conditions are 
required rendering the usefulness of the direct mono-alkylation of aromatics limited 
[18, 19]. The introduction of primary alkyl groups is therefore instead performed 
using multistep protocols [20-30]. These aforementioned drawbacks, as well as the 
challenge of achieving high regioselectivity, also apply to the synthesis of mono-
alkylated estrogenic steroids, such as 2-ethyl estradiol (4a). Towards tackling the 
challenge of developing a regioselective and easy synthesis of 2-ethyl estradiol, we 
reported the application of a highly regioselective ortho-formylation protocol [31-33] 
of estradiols and estrogens [34]. These studies also resulted in a multi-step synthesis 
of 2-ethyl estradiol (4a) [15] that required chromatographic separation of the 2-
substituted salicylaldehyde 8 from its 4-substituted regioisomer 9 (Scheme 1). 
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Scheme 1. Regioselective ortho-formylation of 17β-estradiol (2) yielding the two 
regioisomeric salicylaldehydes 8 and 9. Compound 8 was converted into 2-ethyl 
estradiol (4a). 
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Since 2-substituted alkylated analogs of 2-methoxyestradiol (1), such as 5 and 6 
(Figure 1) displayed interesting inhibition of polymerization of tubulin along with 
cytotoxic and anti-angiogenic effects [13-15], we became interested in conducting 
additional structural-activity relationship studies using 1 as the lead compound. 
Recently Parnes and Pappo reported a convenient and highly regioselective multi-
component reductive alkylation reaction of aromatic compounds [35]. The formation 
of the alkylation product was mediated by an in situ formed thionium ion from an 
aldehyde and ethanethiol under mild catalytic acidic conditions. The resulting 1-
(alkylthio)alkylarenes were reduced by triethyl silane to the mono-alkylated product 
in good to excellent yields. In their successful method development efforts, Parnes 
and Pappo reported two examples using 2 in the aforementioned protocol, affording 
the 2-iso-butyl and 2-benzyl substituted products in 67% and 85% isolated yield, 
respectively. These results spurred our interest in the synthesis and cytotoxic 
evaluations of analogs of 2-methoxyestradiol (1), applying this Pummerer-type 
reaction. These studies are communicated herein. 
2. Experimental 
2.1. General 
Under an inert atmosphere, 17β-estradiol (1) (0.27 g, 1.0 mmol), aldehyde (3.0 mmol), 
copper (II) trifluoromethanesulfonate (9.0 mg, 2.5 mol%), and 2,2,2-trifluoroethanol 
(3.0 mL) were combined in a round-bottom flask. Ethanethiol (0.44 mL, 6.0 mmol) 
was added and the reaction mixture was stirred 16 hours at 50 °C. Triethylsilane (0.48 
mL, 3.0 mmol) was then added and the mixture was allowed to stir for an additional 4 
hours at 50 °C. Analysis by TLC (ethyl acetate:heptane, 30:70) indicated a complete 
reaction. Removal of volatiles was performed in vacuo where the exhaust was passed 
through a solution over basic potassium permanganate solution to quench excess 
ethanethiol. The residue was purified by flash chromatography (ethyl acetate:heptane, 
30:70) to afford the products (4a-4k). 
 
2.2 (8R,9S,13S,14S,17S)-2-Ethyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-
6H-cyclopenta[a]phenanthrene-3,17-diol (4a) [15] 
White solid, 80% yield (0.241 g).  = 82.8 (c = 0.29, MeOH). 1H NMR (400 MHz, 
CDCl3) δ 7.06 (s, 1H), 6.50 (s, 1H), 3.78 – 3.70 (t, J = 8.4 Hz, 1H), 2.87 – 2.72 (m, 
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2H), 2.60 (q, J = 7.6 Hz, 2H), 2.34 (m, 1H), 2.22 – 2.07 (m, 2H), 1.96 (m, 1H), 1.90 – 
1.82 (m, 1H), 1.75 – 1.65 (m, 1H), 1.57 – 1.12 (m, 11H), 0.79 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 151.0, 135.2, 132.3, 127.0, 126.2, 115.0, 81.8, 49.8, 43.8, 43.1, 38.7, 
36.6, 30.4, 29.0, 27.1, 26.2, 23.0, 22.9, 14.2, 10.9. HRMS (EI): Exact mass calculated 
for C20H28O2 [M]+: 300.2089, found 300.2083. 
2.3 (8R,9S,13S,14S,17S)-2-Butyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-
6H-cyclopenta[a]phenanthrene-3,17-diol (4b)[36, 37] 
White solid, 73% yield (0.241 g).	 = 81.8 (c = 0.63, MeOH). 1H NMR (400 MHz, 
CDCl3) δ 7.03 (s, 1H), 6.50 (s, 1H), 4.57 (bs, 1H, OH), 3.73 (t, J = 8.2Hz, 1H),  2.56 
(t, J = 8.0 Hz, 2H), 2.38-2.29 (m, 1H), 2.22-2.08 (m, 2H), 1.99-1.92 (m, 1H), 1.90-
1.81 (m, 1H), 1.75-1.65 (m, 1H), 1.63-1.14 (m, 13H), 0.94 (t, J = 7.3 Hz, 3H) ,0.79 (s, 
3H) .13C NMR (101 MHz, CDCl3) δ 151.4, 135.6, 132.6, 127.26, 126.0, 115.3, 82.1, 
50.2, 44.1, 43.4, 39.0, 36.9, 32.5, 30.7, 29.9, 29.4, 27.4, 26.6, 23.3, 22.9, 14.2, 11.2. 
HRMS (EI): Exact mass calculated for C22H32O2 [M]+: 328.2402, found 328.2404. 
2.4 (8R,9S,13S,14S,17S)-13-Methyl-2-pentyl-7,8,9,11,12,13,14,15,16,17-decahydro-
6H-cyclopenta[a]phenanthrene-3,17-diol (4c)[36] 
White solid, 69% yield (0.236 g).  = 79.0 (c = 0.62, MeOH). 1H NMR (400 MHz, 
CDCl3) δ 7.03 (s, 1H), 6.49 (s, 1H), 3.82 – 3.63 (m, 1H), 2.87 – 2.69 (m, 2H), 2.63 – 
2.47 (m, 2H), 2.41 – 2.29 (m, 1H), 2.23 – 2.04 (m, 2H), 1.99 – 1.91 (m, 1H), 1.91 – 
1.82 (m, 1H), 1.76 – 1.65 (m, 1H), 1.57 (s, 3H), 1.53 – 1.43 (m, 2H), 1.40 – 1.24 (m, 
8H), 1.22 – 1.13 (m, 1H), 0.89 (d, J = 7.3 Hz, 3H), 0.78 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 151.4, 135.6, 132.6, 127.3, 126.0, 115.4, 82.1, 50.2, 44.2, 43.4, 39.1, 36.9, 
32.0, 30.8, 30.1, 30.1, 29.4, 27.4, 26.6, 23.3, 22.7, 14.2, 11.2. HRMS (EI): Exact mass 
calculated for C23H34O2 [M]+: 342.2559, found 342.2555. 
2.5 (8R,9S,13S,14S,17S)-2-Hexyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-
6H-cyclopenta[a]phenanthrene-3,17-diol (4d)[37] 
White solid in 64% yield (0.228 g).  = 69.8 (c = 0.86, MeOH). 1H NMR (400 
MHz, CDCl3) δ 7.03 (s, 1H), 6.49 (s, 1H), 3.91 – 3.59 (m, 1H), 2.88 – 2.69 (m, 2H), 
2.64 – 2.50 (m, 2H), 2.36 – 2.25 (m, 1H), 2.24 – 2.06 (m, 2H), 2.01 – 1.92 (m, 1H), 
1.90 – 1.81 (m, 1H), 1.76 – 1.65 (m, 1H), 1.63 – 1.25 (m, 15H), 1.24 – 1.13 (m, 1H), 
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0.89 (m, 3H), 0.78 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 151.4, 135.6, 132.6, 127.2, 
126.0, 115.4, 82.1, 50.2, 44.1, 43.4, 39.1, 36.9, 31.9, 30.8, 30.3, 30.2, 29.5, 29.4, 27.4, 
26.6, 23.3, 22.8, 14.3, 11.2. HRMS (EI): Exact mass calculated for C24H36O2 [M]+: 
356.2715, found 356.2714. 
2.6 (8R,9S,13S,14S,17S)-2-Isobutyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-
6H-cyclopenta[a]phenanthrene-3,17-diol (4e)[35] 
White solid, 69% yield (0.229 g).  = 75.2 (c = 0.32, CHCl3), (lit. [24] .	 = 
70.8 (CHCl3). 1H NMR (400 MHz, CDCl3) δ 6.98 (s, 1H), 6.50 (s, 1H), 3.74 (m, 1H), 
2.90 – 2.70 (m, 2H), 2.48 – 2.38 (d, 2H), 2.32 (m, 1H), 2.14 (m, 2H), 1.99 – 1.82 (m, 
3H), 1.75 – 1.65 (m, 1H), 1.55 – 1.13 (m, 8H), 0.94 (d, 6H), 0.78 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 151.6, 135.6, 132.4, 128.3, 124.8, 115.3, 82.1, 50.2, 44.1, 43.41, 
39.4, 39.1, 36.9, 30.8, 29.4, 29.26, 27.4, 26.6, 23.3, 22.8, 22.7, 11.2. HRMS (EI): 
Exact mass calculated for C22H32O2 [M]+: 328.2402, found 328.2408. 
2.7 (8R,9S,13S,14S,17S)-13-Methyl-2-neopentyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (4f) 
White solid, 34% yield (0.120 g).  = 85.9 (c = 0.40, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 6.96 (s, 1H), 6.51 (s, 1H), 3.74 (t, J = 8.4 Hz, 1H), 2.86 – 2.76 (m, 2H), 2.47 
(s, 2H), 2.30 (m, 1H), 2.14 (m, 2H), 1.95 (m, 1H), 1.86 (m, 1H), 1.70 (m, 1H), 1.54 – 
1.15 (m, 8H), 0.95 (s, 9H), 0.79 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 152.0, 135.9, 
132.0, 129.9, 122.9, 115.5, 82.1, 50.2, 44.1, 43.4, 43.2, 39.1, 36.9, 32.8, 30.8, 29.7, 
29.3, 27.4, 26.6, 23.3, 11.3. HRMS (EI): Exact mass calculated for C23H34O2 [M]+: 
342.2559, found 342.2553. 
2.8 (8R,9S,13S,14S,17S)-2-Benzyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-
6H-cyclopenta[a]phenanthrene-3,17-diol (4g)[35] 
White solid, 89% yield (0.330 g).  = 60.5 (c = 0.94, CHCl3), (lit. [24]  = 
54.5 (CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.16 (m, 5H), 7.05 (s, 1H), 6.52 
(s, 1H), 4.02 – 3.90 (m, 2H), 3.73 (t, J = 8.7 Hz, 1H), 2.88 – 2.71 (m, 2H), 2.30 – 2.04 
(m, 3H), 1.96 – 1.82 (m, 2H), 1.70 (m, 1H), 1.53 – 1.14 (m, 8H), 0.78 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 151.7, 140.4, 136.5, 132.8, 128.7, 128.7, 128.1, 126.4, 
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124.3, 115.9, 82.1, 50.2, 44.1, 43.4, 39.0, 36.8, 36.6, 30.7, 29.4, 27.4, 26.5, 23.3, 11.2. 
HRMS (EI): Exact mass calculated for C25H30O2 [M]+: 362.2246, found 362.2260. 
2.9 (8R,9S,13S,14S,17S)-2-(4-fluorobenzyl)-13-Methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (4h) 
Pale yellow solid, 70% yield (0.266 g).  = 342.7 (c = 0.33, MeOH). 1H NMR 
(400 MHz, CDCl3) δ 7.22 – 7.16 (m, 2H), 7.02 (s, 1H), 6.99 – 6.92 (m, 2H), 6.51 (s, 
1H), 3.97 – 3.85 (m, 2H), 3.76 – 3.69 (m, 1H), 2.87 – 2.73 (m, 2H), 2.29 – 2.04 (m, 
3H), 1.96 – 1.82 (m, 2H), 1.76-1.66 (m, 1H), 1.74 – 1.13 (m, 8H), 0.78 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 161.6 (d, JCF = 245 Hz), 151.5, 136.6, 136.3 (d, JCF = 
3Hz), 132.9, 130.1 (d, JCF = 8Hz), 128.0, 124.3, 115.8, 115.4 (d, JCF = 21 Hz), 81.1, 
50.2, 44.1, 43.4, 39.0 36.8, 35.6, 30.7, 29.4, 27.4, 26.5, 23.3, 11.2. HRMS (EI): Exact 
mass calculated for C25H29FO2 [M]+: 380.2152, found 380.2157. 
 
2.10 (8R,9S,13S,14S,17S)-2-(4-chlorobenzyl)-13-Methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (4i) 
Pale yellow solid, 89% yield (0.353 g).  = 82.6 (c = 0.84, MeOH). 1H NMR (400 
MHz, CDCl3) δ 7.24 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.5 Hz, 2H), 7.02 (s, 1H), 6.50 
(s, 1H), 3.99 – 3.83 (m, 2H), 3.78 – 3.65 (m, 1H), 2.91 – 2.65 (m, 2H), 2.33 – 2.21 (m, 
1H), 2.21 – 2.06 (m, 2H), 1.99 – 1.81 (m, 2H), 1.75 – 1.08 (m, 9H), 0.93 – 0.85 (m, 
1H), 0.78 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 151.3, 139.1, 136.5, 132.9, 131.8, 
130.0, 128.6, 127.9, 123.9, 115.7, 81.9, 50.0, 43.9, 43.3, 38.9, 36.7, 35.6, 30.6, 29.2, 
27.2, 26.4, 23.1, 11.1. HRMS (EI): Exact mass calculated for C25H29ClO2 [M]+: 
398.1856, found 398.1861. 
2.11 (8R,9S,13S,14S,17S)-2-(4-bromobenzyl)-13-Methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (4j) 
Pale yellow solid, 84% yield (0.371 g).  = 74.3 (c = 1.2, MeOH). 1H NMR (400 
MHz, CDCl3) δ 7.38 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 7.01 (s, 1H), 6.49 
(s, 1H), 3.96 – 3.82 (m, 2H), 3.80 – 3.68 (m, 1H), 2.90 – 2.70 (m, 2H), 2.31 – 2.20 (m, 
1H), 2.21 – 2.05 (m, 2H), 1.97 – 1.81 (m, 2H), 1.76 – 1.62 (m, 1H), 1.54 – 1.11 (m, 
8H), 0.89 (t, J = 6.6 Hz, 1H), 0.78 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 151.3, 
139.7, 136.5, 132.9, 131.5, 130.4, 127.9, 123.8, 119.8, 115.7, 81.9, 50.0, 43.9, 43.3, 
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38.9, 36.7, 35.7, 30.6, 29.3, 27.2, 26.4, 23.1, 11.1. HRMS (EI): Exact mass calculated 
for C25H29BrO2 [M]+: 440.1351, found 440.1348. 
2.12 (8R,9S,13S,14S,17S)-2-(4-methoxybenzyl)-13-Methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (4k)  
White solid, 60% yield (0.237 g).  = 76.8 (c = 0.573, MeOH). 1H NMR (400 
MHz, CDCl3) δ 7.18 – 7.12 (d, J = 8.70 Hz, 2H), 7.04 (s, 1H), 6.86 – 6.80 (d, J = 8.70 
Hz, 2H), 6.52 (s, 1H), 3.95 – 3.83 (m, 2H), 3.78 (s, 3H), 3.73 (t, J = 8.6 Hz, 1H), 2.83 
– 2.75 (m, 2H), 2.27 (m, 1H), 2.21 – 2.04 (m, 2H), 1.90 (m, 2H), 1.77-1.67 (m, 1H), 
1.75 – 1.13 (m, 8H), 0.78 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 158.2, 151.7, 136.5, 
132.8, 132.3, 129.7, 128.0, 124.6, 115.9, 114.2, 82.1, 55.4, 50.2, 44.1, 43.4, 39.0, 36.9, 
35.8, 30.8, 29.4, 27.4, 26.5, 23.3, 11.2. HRMS (EI): Exact mass calculated for 
C26H32O3 [M]+: 392.2351, found 392.2328. 
2.13 Cancer Cell Growth Inhibition  
Human cervical carcinoma (HeLa) cells were seeded in 96-well plates at 15,000 
cells/well in the presence of 5-fold dilutions of the compounds. After 3 days of 
incubation, the cells were trypsinized and counted by means of a Coulter counter 
(Analis, Belgium). Human dermal microvascular endothelial (HMEC-1) cells were 
seeded on gelatin-coated 48-well plates at 20,000 cells/well. After overnight 
incubation, 5-fold dilutions of the compounds were added. Three days later, the cells 
were trypsinized and counted. Human T-cell leukemia (CEM) cells were seeded in 
96-well plates at 60,000 cells/well in the presence of the compounds, allowed to 
proliferate for 4 days and then counted. The 50% inhibitory concentration (IC50) was 
defined as the compound concentration required to reduce cell proliferation by 50% 
[38].  
 
3. Results 
3.1 Chemistry 
The synthesis of the analogs started with the preparation of the steroid 4a as outlined 
in Scheme 2. Commercially available 17β-estradiol (2) was added together with 
acetaldehyde, copper(II) trifluoromethanesulfonate and ethanethiol and stirred in 
2,2,2-trifluoroethanol at 50 °C overnight. Then triethylsilane was added, and the 
mixture was stirred at 50 °C for additional four hours. The desired 2-ethyl substituted 
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estrogen 4a was obtained in excellent 80% isolated yield after chromatographic 
purification. Gratifyingly, only one regioisomer of 4a was detected by HPLC analysis 
of the crude reaction mixture and by comparison with NMR data from literature [34, 
35]. In the 1H NMR spectrum of 4a two singlet signals were observed at 7.06 ppm 
and 6.50 ppm as expected for a 2-substituted estradiol [34, 35]. The singlet at 7.06 
ppm in the 1H NMR spectrum is observed for H1 (Fig, 1), as determined by 
interpretation of the cross peaks detected for this singlet in the HSQC and HMBC 
NMR spectra (see Supporting information). For a 4-substituted estradiol one would 
expect the presence of two doublets with equal ortho-coupling constant integrating for 
one hydrogen each in the aromatic region, as reported earlier [34, 39]. The 13C NMR- 
and the 2D NMR-spectra (COSY45, HSQC and HMBC) also supported the formation 
of 2-ethyl estradiol (see Supporting information). In particular the HMBC-spectrum 
provided additional support for the formation of 2-ethyl estradiol (4a) as the singlet at 
7.06 ppm in the 1H NMR spectrum showed correlation with signals at 22.9 ppm and 
14.2 ppm in the 13C NMR spectrum arising from the CH2- and the CH3-group in the 
ethyl-substituent, respectively. For the other n-alkylated aldehydes subjected to the 
same conditions, good to high yields in the range of 64-73% were observed for the 
products 4b-4d, Scheme 2. Sterically more demanding aldehydes were also tested, 
that returned the desired 2-alkylated estrogen in 69% and 34% isolated yields of 4e 
and 4f, respectively. For 2-neopentyl estradiol (4f) the yield was poor, most likely due 
to the steric hindrance of pivaldehyde. Disappointingly, 3-methylbut-2-enal did not 
return any of the 2-substituted product as only the starting material 2 was recovered. 
The introduction of a prenyl-group in either the 2- or the 4-position of 2 would be of 
interest towards a biomimetic synthesis of naturally occurring terpenoid-derived 
estradiols [40]. When benzaldehydes were used, high (70%) to excellent yields (89%) 
were observed, as observed for products 4g-4j. The electron-releasing para-methoxy 
benzaldehyde resulted in a 60% isolated yield of 4k. Of note, neither 2-thiophene 
carboxaldehyde nor 2-furane carboxaldehyde reacted in this reaction. In both cases 
17β-estradiol (2) was recovered unreacted. The spectral data of all known as well as 
new products were in accord with their assigned structures. Our attempts when using 
estrone or its 17-ethylene acetal with acetaldehyde gave complex reaction mixtures in 
both cases.  
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Scheme 2. Regioselective alkylation of 17β-estradiol (2). 
 
 
3.2 Biological evaluations 
The 2-alkylated analogs were submitted to human T-cell leukemia (CEM), human 
cervix carcinoma (HeLa) and human dermal microvascular endothelial cells (HMEC-
1) for the evaluation of their anti-proliferative effects. The data are expressed as IC50 
(50% inhibitory concentration), which is defined as the compound concentration that 
reduces cell proliferation by 50%, and are shown in Table 1. The reference compound 
2-ME (1) inhibited the growth of all cell lines tested in the low micromolar range 
(IC50 between 0.4 and 1.6 µM). The most potent compound was the 2-ethyl analog 4a 
with IC50 values of 5.6 ± 0.8 and 9.5 ± 0.9 µM towards the CEM and HeLa cell lines, 
respectively. None of the compounds inhibited the growth of the endothelial cell line, 
which may point to a tumor-selective mechanism of action. However, since they were 
less potent than 2-ME (1), no further biological studies were conducted.  
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Table 1. Anti-proliferative activity of 2-alkyl analogs 4a-4k and 2-ME (1) 
  
Compound 
 
CEM 
IC50 (µM )a 
HeLa 
IC50 (µM )a 
HMEC-1 
IC50 (µM )a 
2-ME (1) 1.6 ± 0.9 0.41 ± 0.06 1.3 ± 0.5 
4a 5.6 ± 0.8 9.5 ± 0.9 > 50 
4b 24 ± 10 29 ± 0 > 50 
4c 25 ± 8 27 ± 5 > 50 
4d 18 ± 7 21 ± 4 > 50 
4e 25 ± 8 24 ± 5 > 50 
4f 36 ± 2 43 ± 7 > 50 
4g 15 ± 0 27 ± 6 > 50 
4h 35 ± 1 33 ± 11 > 50 
4i 31 ± 1 33 ± 11 > 50 
4j 19 ± 12 31 ± 14 > 50 
4k 15 ± 3 25 ± 2 > 50 
a Results of three experiments performed as duplicates 
 
4. Conclusions 
Structure-activity relationship (SAR) studies have shown that the endogenously 
formed metabolite of 17β-estradiol (2), namely 2-methoxyestradiol (1), is amendable 
for changes in the 2-position of the A-ring [41]. Several alkyl substituents in this 
position were easily introduced in 2 using a recently reported one-pot protocol [35]. 
The yields of the alkylated products were high to excellent, except for one example. 
This one-pot protocol is easy to conduct compared to the multi-step protocols 
previously reported [15, 36, 37, 42]. One-pot protocols offer many advantages, such 
as avoiding isolation, handling and chromatography of intermediates leading to time-
cost benefits. The 17-acetate of 17β-estradiol (2), estrone and its ethylene-acetal did 
not react in this protocol. The 2-ethyl analog of 17β-estradiol (2), which displayed 
selective and decent cytotoxic effects, should be useful as a lead compound for further 
structural-activity studies where alterations are to be performed at the C17-position. 
Such analogs are of interest towards the development of novel analogs of 2-ME (1) 
[43]. 
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